BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

31 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery and Characterization of a New Class of C5aR1 Antagonists Showing In Vivo Activity.EBI
Idorsia Pharmaceuticals
Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats.EBI
Idorsia Pharmaceuticals
Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies.EBI
Idorsia Pharmaceuticals
Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125.EBI
Idorsia Pharmaceuticals
Discovery and EBI
Idorsia Pharmaceuticals
Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239.EBI
Idorsia Pharmaceuticals
Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.EBI
Idorsia Pharmaceuticals
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.EBI
Idorsia Pharmaceuticals
Discovery and evaluation of CaEBI
Idorsia Pharmaceuticals
Discovery and evaluation of CaEBI
Idorsia Pharmaceuticals
COMBINATION OF DUAL ATM AND DNA-PK INHIBITORS AND IMMUNOTHERAPEUTIC AGENTS FOR USE IN CANCER THERAPYBDB
XRAD Therapeutics
TRICYCLIC PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORSBDB
Jazz Pharmaceuticals Ireland
MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOFBDB
Insilico Medicine IP
8-(PICOLINAMIDE) SUBSTITUTED COUMARIN COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOFBDB
Longivitron (Suzhou) Biotechnology
NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOFBDB
Jacobio Pharmaceuticals
INHIBITORS OF METTL3BDB
Strom Therapeutics
SSTR4 agonist saltsBDB
Eli Lilly
MODULATORS OF ALPHA-1 ANTITRYPSINBDB
Vertex Pharmaceuticals
INDAZOLE DERIVATIVES AS INHIBITORS OF SARM1BDB
Disarm Therapeutics
Pyrazolyl derivatives useful as anti-cancer agentsBDB
Novartis
Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitorsBDB
Mekanistic Therapeutics
Aromatic compound, pharmaceutical composition and use thereofBDB
Sichuan Kelun-Biotech Biopharmaceutical
3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathiesBDB
Ctxt
Design, synthesis and evaluation of new thiazole-piperazines as acetylcholinesterase inhibitors.BDB
Anadolu University
PI3K and/or mTOR inhibitorBDB
Xuanzhu Pharma
Dihydropyridinone MGAT2 inhibitorsBDB
Bristol-Myers Squibb
Synthesis, biological evaluation and docking studies of 2,3-dihydroquinazolin-4(1H)-one derivatives as inhibitors of cholinesterases.BDB
University of Sargodha
Site-specific inhibitory mechanism for amyloid ß42 aggregation by catechol-type flavonoids targeting the Lys residues.BDB
Kyoto University
Derivatives form better lipoxygenase inhibitors than piperine: in vitro and in silico study.BDB
Kannur University, Thalassery Campus